These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
695 related articles for article (PubMed ID: 26796263)
1. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263 [TBL] [Abstract][Full Text] [Related]
2. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173 [TBL] [Abstract][Full Text] [Related]
3. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826 [TBL] [Abstract][Full Text] [Related]
4. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway. Lu PW; Li L; Wang F; Gu YT J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819 [TBL] [Abstract][Full Text] [Related]
5. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200 [TBL] [Abstract][Full Text] [Related]
6. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells. Nguyen Hoang AT; Hoe KL; Lee SJ PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751 [TBL] [Abstract][Full Text] [Related]
7. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905 [TBL] [Abstract][Full Text] [Related]
8. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells. Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049 [TBL] [Abstract][Full Text] [Related]
10. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162 [TBL] [Abstract][Full Text] [Related]
11. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069 [TBL] [Abstract][Full Text] [Related]
12. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Li J; Lu M; Jin J; Lu X; Xu T; Jin S Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449 [TBL] [Abstract][Full Text] [Related]
13. Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy. Liu ZR; Song Y; Wan LH; Zhang YY; Zhou LM Life Sci; 2016 Mar; 149():104-13. PubMed ID: 26896688 [TBL] [Abstract][Full Text] [Related]
14. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778 [TBL] [Abstract][Full Text] [Related]
15. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Shin SY; Lee KS; Choi YK; Lim HJ; Lee HG; Lim Y; Lee YH Carcinogenesis; 2013 Sep; 34(9):2080-9. PubMed ID: 23689352 [TBL] [Abstract][Full Text] [Related]
16. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells. Kim HS; Tian L; Jung M; Choi SK; Sun Y; Kim H; Moon WK PLoS One; 2015; 10(10):e0141110. PubMed ID: 26496360 [TBL] [Abstract][Full Text] [Related]
18. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
19. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway. Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209 [TBL] [Abstract][Full Text] [Related]
20. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]